The abstract is read at the publisher; the summary is JClub's.
In anti-PD-(L)1 resistant advanced non-small cell lung cancer, ceralasertib plus durvalumab shows modestly higher 24-week durable clinical benefit in KRAS-mutant (37.7%) than KRAS-wild type (29.3%).
- Why it matters: KRAS-mutant lung adenocarcinoma can resist immune checkpoint blockade, and preclinical work suggested ATR inhibition might reverse that resistance.
- What they did: In the National Lung Matrix Trial, oral ceralasertib (240 mg twice daily on days 15–28) plus durvalumab (1500 mg IV day 1 every 28 days) was tested in two prospective cohorts (J1 KRAS-mutant, NAJ KRAS-wild type), with Bayesian estimates of 24-week durable clinical benefit.
- The result: Objective responses occurred in 2 evaluable patients, both KRAS-mutant, while KRAS mutation increased ceralasertib-induced micronuclei and blunted KRAS-mediated STAT1 downregulation, implying ATR inhibition affects tumor-cell immunobiology without clear outcome separation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.